Information on the EQA test Tumour cytogenetics


The ring trail aims at the evaluation of the entire process of the chromosome banding analysis in haematological neoplasias starting with the receipt of the sample and ending with the outgoing report.

Performance interval

Once per year.


A surrogate blood sample is generated by using cell lines. The sample is sent out with a fictitious request. The request includes a diagnostic question, which needs to be answered by a chromosome banding analysis.


The analysis has to be carried out according to the own laboratory standard operational procedures. For evaluation, the findings have to be submitted in a written diagnostic report.


Proof of target aberrations through chromosome banding analysis, correct karyotype, correct report of findings.
The identification of a defined target aberration is prerequisite to attest a successful participation in the EQA test.


A certificate will be provided that states the (successful) participation in the trial. The certificate is valid for two years.

EQA test supervisor

Prof. Dr. med. Harald Rieder
Universitätsklinikum Düsseldorf, Institut für Humangenetik
Universitätsstraße 1
40225 Düsseldorf

Dr. rer. nat. Karin Hardt
Universitätsklinikum Düsseldorf, Institut für Humangenetik
Universitätsstr. 1
40225 Düsseldorf

If you would like to contact the EQA test supervisor(s), please call or e-mail the Coordination Office QA of BVDH:
Phone: +49 2403 83 80 54

Status as of: May/2020